September 29, 2016 2:19 AM ET

Biotechnology

Company Overview of Hepregen Corporation

Company Overview

Hepregen Corporation develops bio-engineered solutions for drug discovery and development applications in the pharmaceutical industry. The company develops and commercializes HepatoPac, a bio-engineered micro-liver platform for use in a range of applications, including metabolite identification, toxicity screening, clearance, drug-drug interactions, transporter involvement, in silico models, toxicogenomics, and disease modeling applications in humans; and HepatoMune, a micro-liver assay kit to predict toxicologic outcomes caused by the interaction of drugs and/or biologics with an inflamed liver. Its solutions are also used in cosmetic and environmental testing industries. The company was fo...

200 Boston Avenue

Suite 1500

Medford, MA 02155

United States

Founded in 2007

Phone:

781-391-0205

Fax:

781-391-0315

Key Executives for Hepregen Corporation

Chief Executive Officer and Director
Age: 69
Co-Founder, President and Director
Co-Founder and Director of Research
Chief Financial Officer and Vice President of Finance and Administration
Age: 62
Vice President of Operations
Compensation as of Fiscal Year 2016.

Hepregen Corporation Key Developments

BioTime, Inc. Announces Joint Venture with Hepregen Corporation

BioTime, Inc. and Hepregen Corporation have formed a joint venture company Ascendance Biotechnology, Inc. focused on the in vitro cell biology. As part of the transaction, Ascendance combines Hepregen's application-directed, cellular micro-patterning drug and chemical screening technologies with BioTime's ESI BIO research products and proprietary stem cell technologies. Ascendance will offer a portfolio of current and new stem-cell-derived assays and other products and services to pharmaceutical and chemical companies. In exchange for its contribution of certain assets relating to its research products and related patents and technology, BioTime will acquire a majority equity position in Ascendance. Ascendance will continue to market Hepregen's well-known HepatoPac(R) and HepatoMune(R) micro-patterned liver products, and plans to develop new and unique cell-based and micro-patterned products using BioTime's stem cell technologies and broad intellectual property and product portfolio, including BioTime's PureStem(R) embryonic progenitors and ESI embryonic stem cells. Ascendance also expects to develop additional stem-cell-derived products that will be useful for toxicity testing in the cosmetic, environmental, and food industries.

SOLVO Biotechnology and Hepregen Corp. Sign Co-Marketing Pact

SOLVO Biotechnology and Hepregen Corp. reported the Study of Xenobiotics, a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen's human, monkey, rat and dog application-directed HepatoPac and HepatoMune kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies. These kits contain human or animal hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to make services available to its customers using these Hepregen products as well as HepatoPac B-CLEAR products co-developed by Hepregen and Qualyst Transporter Solutions.

Hepregen Corporation Launches First Dog HepatoPac Assay Kit to Evaluate Metabolism in the Laboratory

Hepregen Corporation announced the commercial launch of the company's first dog HepatoPac kit designed specifically for metabolite identification and profiling applications. Each kit contains one or more standard 24-well tissue culture plates featuring uniquely configured micro-patterned dog liver cells co-cultured with specially selected stromal cells that support the high level of performance observed in Hepregen's micro-patterned co-culture platform. The dog liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for evaluation of the metabolism of chemical agents, including drug candidates, improving the design of preclinical experiments. The remarkable flexibility of Hepregen's micro-patterned HepatoPacĀ® platform allowed Hepregen scientists to develop a dog product that provides investigators with uniquely stable canine hepatocytes. The tissue culture maintains functionality and morphology for weeks, enabling experiments not previously possible.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hepregen Corporation, please visit www.hepregen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.